Beautiful Virgin Islands

Thursday, Oct 02, 2025

AstraZeneca and Oxford defend Covid vaccine trials after questions raised in the U.S.

AstraZeneca and Oxford defend Covid vaccine trials after questions raised in the U.S.

“We believe that this product will never be licensed in the U.S.,” one group of critical U.S.-based analysts wrote this week.

AstraZeneca and the University of Oxford are defending the results and methods used in their phase three vaccine trials on the back of criticism from experts in the U.S., stressing the “highest standards” were used and that “additional analysis will be conducted.”

AstraZeneca shares are down by around 6% this week after questions were raised over its vaccine candidate, for which the company said combined results revealed it to be 70% effective. The figure came from combining a smaller group of people who received an unintentionally lower dose of the vaccine — and by what a company spokesperson has called “serendipity” — produced 90% effectiveness, and a larger group who received a higher dosage, showing only 62% effectiveness.

Pascal Soriot, CEO of AstraZeneca, confirmed to Bloomberg on Thursday the British pharmaceutical giant was likely to run an additional global trial to evaluate the efficacy of its Covid-19 vaccine.

Chief of the White House’s Operation Warp Speed, Moncef Slaoui, and others in the U.S. have expressed concern over the age group tested, saying 90% efficacy was only shown for the lowest risk group, which numbered 2,741 people below the age of 55. The group whose results displayed 62% effectiveness numbered 8,895.

AstraZeneca pushed back against the criticism, emphasizing monitoring of the study by the external Data Safety Monitoring Board (DSMB) and the fact that the data released Monday constituted mere interim results and that more data would follow.

“The studies were conducted to the highest standards,” a spokesperson for AstraZeneca told CNBC on Thursday. “An independent DSMB safety monitoring committee oversees the studies to ensure safety and quality. The DSMB determined that the analysis met its primary endpoint showing protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine.”

“More data will continue to accumulate and additional analysis will be conducted refining the efficacy reading and establishing the duration of protection,” the spokesperson said.


The University of Oxford, for its part, explained the discrepancy between dosage allotments. It said an initial over-estimation of the dose of the new vaccine batches had resulted “in a half dose of the vaccine being administered as the first dose” due to a “difference in the manufacturing process.”

“The methods for measuring the concentration are now established and we can ensure that all batches of vaccine are now equivalent,” it added.

Harsh criticism


Particularly harsh criticism came from U.S.-based health care and biotech investment bank SVB Leerink, whose analysts wrote Monday: “We believe that this product will never be licensed in the U.S.”

“This belief is based on the design of the company’s pivotal trials which does not appear to match the FDA’s requirements for representation of minorities, severe cases, previously infected individuals and elderly and other increase risk populations,” the analysis said.

In response, a spokesperson at AstraZeneca stressed the results were interim and that more data was to be accumulated and more analysis to be carried out.

Defenders of the trials have pointed out that the criticism seems to come primarily from within the U.S., home of the only other Western vaccine candidates to announce higher effectiveness in their vaccine test results: Pfizer-BioNTech and Moderna, who earlier this month announced their vaccines showed as much as 95% effectiveness.


John LaMattina, a former president of Pfizer Global R&D, tweeted on Tuesday: “Hard to believe that the FDA will issue an EUA for a vaccine whose optimal dose has only been given to 2,300 people. More data for this dosing regiment will be needed.” Slaoui was previously on the board at Moderna and also worked at GlaxoSmithKline.

Cost, distribution, logistics


Outside of the U.S., the Oxford-AstraZeneca vaccine garnered praise, particularly for its relative ease of manufacturing and transport and its low cost compared to potential competitors. The vaccine would sell at between $3 and $5 per dose while those of Pfizer-BioNTech and Moderna would go for $20 per dose and $32 to $37 per dose, respectively.

The Pfizer-BioNTech vaccine candidate, as an mRNA vaccine, also requires extremely cold storage temperatures of negative 94 degrees Fahrenheit and special transport equipment. The Moderna vaccine can be stored for up to six months at minus 4 degrees Fahrenheit.


The Oxford-Astrazeneca results “are very positive results when we recall that the hurdle for a good enough vaccine was set at 50-60%, in line with the flu virus,” Dr. Gillies O’Bryan-Tear, policy chair at the U.K.-based Faculty of Pharmaceutical Medicine, said Monday.

“The great advantage of this Oxford vaccine over the mRNA vaccines is that it can be manufactured easily and transported at ordinary fridge (not freezer) temperatures, so can be transported and stored using the existing vaccine cold chain infrastructure. The group has promised to provide the vaccine not-for-profit to developing nations.”

AstraZeneca has said its vaccine can be stored, transported and handled at normal refrigerated conditions (36-46 degrees Fahrenheit) for at least six months and administered within existing health-care settings. It has also pledged to distribute the vaccine at no profit “for the duration of the pandemic.”

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Trump Administration Launches “TrumpRx” Plan to Enable Direct Drug Sales at Deep Discounts
Trump Announces Intention to Impose 100 Percent Tariff on Foreign-Made Films
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Singapore and Hong Kong Vie to Dominate Asia’s Rising Gold Trade
Trump Organization Teams with Saudi Developer on $1 Billion Trump Plaza in Jeddah
Manhattan Sees Surge in Office-to-Housing Conversions, Highest Since 2008
Switzerland and U.S. Issue Joint Assurance Against Currency Manipulation
Electronic Arts to Be Taken Private in Historic $55 Billion Buyout
Thomas Jacob Sanford Named as Suspect in Deadly Michigan Church Shooting and Arson
Russian Research Vessel 'Yantar' Tracked Mapping Europe’s Subsea Cables, Raising Security Alarms
New York Man Arrested After On-Air Confession to 2017 Parents’ Murders
U.S. Defense Chief Orders Sudden Summit of Hundreds of Generals and Admirals
Global Cruise Industry Posts Dramatic Comeback with 34.6 Million Passengers in 2024
Trump Claims FBI Planted 274 Agents at Capitol Riot, Citing Unverified Reports
India: Internet Suspended in Bareilly Amid Communal Clashes Between Muslims and Hindus
Supreme Court Extends Freeze on Nearly $5 Billion in U.S. Foreign Aid at Trump’s Request
Archaeologists Recover Statues and Temples from 2,000-Year-Old Sunken City off Alexandria
China Deploys 2,000 Workers to Spain to Build Major EV Battery Factory, Raising European Dependence
Speed Takes Over: How Drive-Through Coffee Chains Are Rewriting U.S. Coffee Culture
U.S. Demands Brussels Scrutinize Digital Rules to Prevent Bias Against American Tech
Ringo Starr Champions Enduring Beatles Legacy While Debuting Las Vegas Art Show
Private Equity’s Fundraising Surge Triggers Concern of European Market Shake-Out
Colombian President Petro Vows to Mobilize Volunteers for Gaza and Joins List of Fighters
FBI Removes Agents Who Kneeled at 2020 Protest, Citing Breach of Professional Conduct
Trump Alleges ‘Triple Sabotage’ at United Nations After Escalator and Teleprompter Failures
Shock in France: 5 Years in Prison for Former President Nicolas Sarkozy
Tokyo’s Jimbōchō Named World’s Coolest Neighbourhood for 2025
European Officials Fear Trump May Shift Blame for Ukraine War onto EU
BNP Paribas Abandons Ban on 'Controversial Weapons' Financing Amid Europe’s Defence Push
Typhoon Ragasa Leaves Trail of Destruction Across East Asia Before Making Landfall in China
The Personality Rights Challenge in India’s AI Era
Big Banks Rebuild in Hong Kong as Deal Volume Surges
Italy Considers Freezing Retirement Age at 67 to Avert Scheduled Hike
Italian City to Impose Tax on Visiting Dogs Starting in 2026
Arnault Denounces Proposed Wealth Tax as Threat to French Economy
Study Finds No Safe Level of Alcohol for Dementia Risk
Denmark Investigates Drone Incursion, Does Not Rule Out Russian Involvement
Lilly CEO Warns UK Is ‘Worst Country in Europe’ for Drug Prices, Pulls Back Investment
Nigel Farage Emerges as Central Force in British Politics with Reform UK Surge
Disney Reinstates ‘Jimmy Kimmel Live!’ after Six-Day Suspension over Charlie Kirk Comments
U.S. Prosecutors Move to Break Up Google’s Advertising Monopoly
Nvidia Pledges Up to $100 Billion Investment in OpenAI to Power Massive AI Data Center Build-Out
U.S. Signals ‘Large and Forceful’ Support for Argentina Amid Market Turmoil
Nvidia and Abu Dhabi’s TII Launch First AI-&-Robotics Lab in the Middle East
Vietnam Faces Up to $25 Billion Export Loss as U.S. Tariffs Bite
Europe Signals Stronger Support for Taiwan at Major Taipei Defence Show
Indonesia Court Upholds Military Law Amid Concerns Over Expanded Civilian Role
Larry Ellison, Michael Dell and Rupert Murdoch Join Trump-Backed Bid to Take Over TikTok
Trump and Musk Reunite Publicly for First Time Since Fallout at Kirk Memorial
Vietnam Closes 86 Million Untouched Bank Accounts Over Biometric ID Rules
×